Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $864,302 - $945,689
-2,120 Reduced 5.87%
34,007 $14.2 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $5.74 Million - $6.87 Million
-16,729 Reduced 31.65%
36,127 $14.7 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $1.69 Million - $1.81 Million
-4,988 Reduced 8.62%
52,856 $18.4 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $3.26 Million - $3.65 Million
10,359 Added 21.82%
57,844 $20.4 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $12.7 Million - $14.5 Million
44,951 Added 1773.91%
47,485 $15 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $340,625 - $383,204
1,192 Added 88.82%
2,534 $731,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $370,218 - $413,076
-1,352 Reduced 50.19%
1,342 $389,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $632,982 - $788,129
2,694 New
2,694 $759,000
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $493,545 - $581,702
-2,229 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $394,555 - $498,070
2,229 New
2,229 $489,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $253,039 - $283,171
-1,395 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $50,059 - $59,033
-267 Reduced 16.06%
1,395 $281,000
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $344,067 - $401,057
1,662 New
1,662 $357,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $202,455 - $270,016
-978 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $250,025 - $296,431
978 New
978 $266,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $238,557 - $312,956
-1,058 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $176,379 - $236,896
1,058 New
1,058 $232,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Lombard Odier Asset Management (Switzerland) Sa Portfolio

Follow Lombard Odier Asset Management (Switzerland) Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.